Sinovac Biotech Ltd. Files 20-F Annual Report for Fiscal Year 2023

TL;DR

<b>Sinovac Biotech Ltd. has submitted its 20-F annual report for the fiscal year 2023, detailing its financial and operational status.</b>

AI Summary

SINOVAC BIOTECH LTD (SVA) filed a Foreign Annual Report (20-F) with the SEC on April 29, 2024. Sinovac Biotech Ltd. filed its 20-F annual report for the fiscal year ending December 31, 2023. The filing covers the period from January 1, 2023, to December 31, 2023. The company's principal business address is located at No. 39 Shangdi Xi Road, Haidian District, Beijing, China. Sinovac Biotech Ltd. was formerly known as Net Force Systems Inc. before a name change on November 10, 1999. The filing includes various financial disclosures and operational details for the reporting period.

Why It Matters

For investors and stakeholders tracking SINOVAC BIOTECH LTD, this filing contains several important signals. This 20-F filing provides a comprehensive overview of Sinovac Biotech's financial performance and business operations for the fiscal year 2023, which is crucial for investors to assess the company's health and future prospects. The report contains detailed information on assets, liabilities, equity, and other financial metrics, enabling stakeholders to make informed investment decisions and understand the company's compliance with SEC regulations.

Risk Assessment

Risk Level: medium — SINOVAC BIOTECH LTD shows moderate risk based on this filing. The company's business is subject to significant regulatory oversight in the pharmaceutical industry, and changes in regulations or failure to comply could materially impact its operations and financial results.

Analyst Insight

Investors should review the detailed financial statements and risk factors outlined in the 20-F filing to understand Sinovac Biotech's current financial position and potential future challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Reporting Period)
• 2024-04-29 — Filing Date (Date of Submission)
• 1934 Act — SEC Act (Governing Legislation)
• 001-32371 — SEC File Number (Company's SEC File Number)

Key Players & Entities

• SINOVAC BIOTECH LTD (company) — Filer
• NET FORCE SYSTEMS INC (company) — Former Company Name
• 2023-12-31 (date) — Fiscal Year End
• 2024-04-29 (date) — Filing Date
• No. 39 Shangdi Xi Road, Haidian District, Beijing (address) — Business Address
• 0000950170-24-049936 (filing_id) — Accession Number

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The company's operations are subject to extensive government regulations in the pharmaceutical industry, and changes in these regulations or non-compliance could adversely affect its business.
• Market Competition [medium — market]: The biotechnology and pharmaceutical markets are highly competitive, and the company faces competition from other companies that may have superior products or greater resources.
• Operational Challenges [medium — operational]: The company may face operational challenges related to research and development, manufacturing, and distribution of its products.

Key Dates

• 2023-12-31: Fiscal Year End — End of the reporting period for the 20-F filing.
• 2024-04-29: Filing Date — Date the 20-F report was officially submitted to the SEC.

Key Financial Figures

• $0.001 — h registered Common Shares, par value $0.001 per share Preferred Share Purchase Ri
• $1 — ars were made at a rate of RMB7.0999 to $1.00, the exchange rate in effect as set
• $1.00 — Reserve Exchange Rate was RMB7.2403 to $1.00. FORWARD-LOOKING INFORMATION This a
• $4 million — 2023, except for a loan in an amount of $4 million repaid by Sinovac Dalian to Sinovac Ant

Filing Documents

• sva-20231231.htm (20-F) — 4559KB
• sva-ex8_1.htm (EX-8.1) — 13KB
• sva-ex12_1.htm (EX-12.1) — 12KB
• sva-ex12_2.htm (EX-12.2) — 12KB
• sva-ex13_1.htm (EX-13.1) — 6KB
• sva-ex13_2.htm (EX-13.2) — 6KB
• sva-ex15_1.htm (EX-15.1) — 5KB
• sva-ex97_1.htm (EX-97.1) — 38KB
• img57734221_0.jpg (GRAPHIC) — 37KB
• img57734221_1.jpg (GRAPHIC) — 188KB
• 0000950170-24-049936.txt (&nbsp;) — 17911KB
• sva-20231231.xsd (EX-101.SCH) — 2210KB
• sva-20231231_htm.xml (XML) — 3265KB

Item 18

Item 17 Item 18 If this is an annual report, indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No (APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PAST FIVE YEARS) Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes No CON TENTS INTRODUCTION 1 FORWARD-LOOKING INFORMATION 1 PART I 3 ITEM 1. Identity of Directors, Senior Management and Advisers 3 ITEM 2. Offer Statistics and Expected Timetable 3 ITEM 3. Key Information 3 ITEM 4. Information on the Company 37 ITEM 4A. Unresolved Staff Comments 54 ITEM 5. Operating and Financial Review and Prospects 54 ITEM 6. Directors, Senior Management and Employees 67 ITEM 7. Major Shareholders and Related Party Transactions 76 ITEM 8. Financial Information 77 ITEM 9. The Offer and Listing 82 ITEM 10. Additional Information 83 ITEM 11.

Quantitative and Qualitative Disclosures about Market Risk

Quantitative and Qualitative Disclosures about Market Risk 96 ITEM 12.

Description of Securities other than Equity Securities

Description of Securities other than Equity Securities 97 PART II 97 ITEM 13. Defaults, Dividend Arrearages and Delinquencies 97 ITEM 14. Material Modifications to the Rights of Security Holders and Use of Proceeds 97 ITEM 15.

Controls and Procedures

Controls and Procedures 98 ITEM 16A. Audit Committee Financial Expert 99 ITEM 16B. Code of Ethics 99 ITEM 16C. Principal Accountant Fees and Services 99 ITEM 16D. Exemptions from the Listing Standards for Audit Committees 100 ITEM 16E. Purchases of Equity Securities by the Issuer and Affiliated Purchasers 100 ITEM 16F. Change in Registrant's Certifying Accountant 100 ITEM 16G. Corporate Governance 100 ITEM 16H. Mine Safety Disclosure 100 ITEM 16I. Disclosure Regarding Foreign Jurisdictions That Prevent Inspections 100 ITEM 16J. Insider Trading Policies 100 ITEM 16K Cybersecurity 100 PART III ITEM 17.

Financial Statements

Financial Statements 102 ITEM 18.

Financial Statements

Financial Statements 102 ITEM 19. Exhibits 102 INTRODUCTION In this annual report on Form 20-F, unless otherwise indicated or unless the context otherwise requires, "Sinovac", "Sinovac Biotech", "Company", "we", "us", "our company", and "our" refer to Sinovac Biotech Ltd., its predecessor entities and its consolidated subsidiaries; "Sinovac Antigua" refers to Sinovac Biotech Ltd.; "China", "Chinese" or the "PRC" refers to the People's Republic of China, including Taiwan and the special administrative regions of Hong Kong and Macau, and only in the context of describing the laws, rules, regulations, regulatory authorities in mainland China, and any mainland China entities or citizens under such rules, laws and regulations and other legal or tax matters in this annual report on Form 20-F, excluding, Taiwan and the special administrative regions of Hong Kong and Macau; "mainland China" refers to the People's Republic of China excluding, for the purposes of this annual report only, Taiwan, Hong Kong and Macau; "Mainland China Subsidiaries" refer to our operating subsidiaries in mainland China, namely Sinovac Beijing Co., Ltd. ("Sinovac Beijing"), Sinovac (Dalian) Vaccine Technology Co., Ltd.("Sinovac Dalian"), Sinovac Life Sciences Co., Ltd. ("Sinovac LS"), Sinovac Biomed Co., Ltd. ("Sinovac Biomed") and their respective subsidiaries in the mainland China; "RMB" or "renminbi" refers to the legal currency of China; and "$" or "U.S. dollars" refers to the legal currency of the United States; "shares" or "common shares" refers to Sinovac Antigua's common shares, par value $0.001 per share; and "U.S. GAAP" refers to generally accepted accounting principles in the United States. Discrepancies in any table between the amounts identified as total amounts and the sum of the amounts listed therein are due to rounding. This annual report contains translations of certain renminbi amounts into U.S. dollars at specified rates solely for the convenienc

Identity of Directors, Senior Management and Advisers

ITEM 1. Identity of Directors, Senior Management and Advisers Not applicable.

Offer Statistics and Expected Timetable

ITEM 2. Offer Statistics and Expected Timetable Not applicable.

Key Information

ITEM 3. Key Information Permissions Required from the PRC Authorities for Our Operations We conduct our business primarily through our Mainland China Subsidiaries. Our operations in mainland China are governed by PRC laws and regulations. We believe that our Mainland China Subsidiaries have received all the material licenses, permissions and approvals from the PRC authorities as are necessary for their material business operations in mainland China, and none of such permissions or approvals have been denied. Apart from the permits and licenses above, we are subject to extensive, costly and rigorous regulation by governmental authorities in the PRC and in other countries and we may not be able to maintain or obtain applicable regulatory approvals. See "Item 3. Key Information—D. Risk Factors—Risks Related to Government Regulation—We can only sell products that have received regulatory approvals. Many factors affect our ability to obtain such approvals. We face various legal and operational risks and uncertainties associated with having a portion of our operations in mainland China and the complex and evolving PRC laws and regulations. For example, we face risks associated with regulatory approvals on offerings conducted overseas and foreign investment in mainland China-based issuers, anti-monopoly regulatory actions, and oversight on cybersecurity and data privacy, which may negatively impact our ability to conduct certain businesses or access foreign investments. These risks could result in a material adverse change in our operations and the value of Sinovac Antigua's common shares, significantly limit or completely hinder our ability to conduct business, accept foreign investments, offer or continue to offer securities to investors, continue to be listed on a U.S. or other foreign exchange, or cause the value of such securities to significantly decline or become worthless. For more detailed information, see "—D. Risk Factors—Risks Relating to Doing Business i